Nicholas Fidelman

MD

Director, Interventional Oncology, San Francisco
Interventional radiologist

About me

Dr. Nicholas Fidelman is a radiologist who specializes in caring for patients with liver cancer, metastatic colorectal cancer and neuroendocrine tumors. He has expertise in liver-directed therapy, a treatment that directly targets cancer in the liver. He also is experienced in treating portal hypertension (high blood pressure in the veins connecting the digestive organs to the liver), biliary disorders (which affect the bile ducts and gallbladder), urinary system disorders, and in performing dialysis interventions (minimally invasive procedures to restore blood flow in vessels used for dialysis).

Fidelman's research focuses on clinical trials investigating novel treatments for liver cancer, outcomes of commonly performed procedures in interventional radiology, and on improving the safety and efficacy of image-guided treatments.

Fidelman earned his medical degree from UCSF, where he also completed a residency in radiology and a fellowship in vascular and interventional radiology.

  • Education

    UCSF School of Medicine, 2002

  • Residencies

    UCSF, Radiology, 2007

  • Fellowships

    UCSF, Vascular and Inteventional Radiology, 2008

  • Academic Title

    Associate Professor

  • Languages

    Russian

Conditions I specialize in

Center for Neuroendocrine Tumors

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

(415) 476-2212
M-F, 8:30 a.m. - 5 p.m.

Gastrointestinal Surgical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fourth Floor
San Francisco, CA 94158

(415) 502-5577
M-F, 8 a.m. - 5 p.m.

Interventional Radiology Clinic

505 Parnassus Ave., Room M-361
San Francisco, CA 94143

(415) 353-1300
M-F, 8:30 a.m. - 5 p.m.

Selected research

See all research
Decorative Caduceus

Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine...

The point estimate and 95% confidence interval of overall response rate will be obtained for each of the three liver-directed therapy groups (cryoablation, transarterial embolization(TAE) , radioembolization (RE)) separately. The ...

Recruiting

Decorative Caduceus

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Hepatic progression-free interval (H-PFS)

Recruiting

Decorative Caduceus

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver...

Any adverse events grade ≥ 3 will be reviewed by the treating interventional radiologist and medical oncologist within 24 hours of being informed event. If none of the 3 patients in a cohort experiences a DLT, another 3 patients w...

Recruiting

Contact me

Providers on my team

Share